Hostname: page-component-848d4c4894-4rdrl Total loading time: 0 Render date: 2024-06-16T07:17:22.107Z Has data issue: false hasContentIssue false
  • English
  • Français

Does the use of proton pump inhibitors in children affect ventricular repolarisation parameters?

Published online by Cambridge University Press:  02 May 2022

Onur Tasci Open the ORCID record for Onur Tasci [Opens in a new window]  and
Ezgi Kiran Tasci
Onur Tasci*
Affiliation:
Department of Pediatric Cardiology, Sivas Numune Hospital, Sivas, Turkey
Ezgi Kiran Tasci
Affiliation:
Department of Pediatric Gastroenterology, Hepatology and Nutrition, Sivas Numune Hospital, Sivas, Turkey
*
Author for correspondence: O. Tasci, Department of Paediatric Cardiology, Sivas Numune Hospital, 58050 Sivas, Turkey. Tel: +90 505 751 78 57; Fax: (0 346) 223 95 30. E-mail: dr_onurtasci@hotmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Proton pump inhibitors are widely used agents in the treatment of dyspepsia, and their effects on ventricular repolarisation through ion channels are well-known. Our aim is to evaluate the change in ventricular repolarisation parameters on electrocardiogram before and after proton pump inhibitor treatment. This study included 69 patients who had symptoms such as burning stomach pain, bloating, nausea, and heartburn for at least 3 months. Electrolyte levels of the patients were measured before and after treatment, and 12-lead electrocardiograms were taken at the initial and 1st month follow-up visit. Heart rate, QT interval, corrected QT (QTc), QT dispersion (QTd), QTc dispersion (QTcd), Tp-e measurements, and Tp-e/QT ratio were calculated and compared. Thirty-nine of the patients were girls, 30 were boys, and the mean age was 13.16 ± 3.02 years. Electrolyte levels of the patients before and after treatment were within the normal range. There was no statistically significant difference in the QTc, the Tp-e duration, or the Tp-e/QT ratio of the patients before and after treatment. We did not find a significant prolongation in the QTc duration or any other ventricular repolarisation parameters after proton pump inhibitor treatment in children with dyspepsia. We did not observe ventricular arrhythmia in our patients during follow-up. However, different results might be obtained with a larger sample and a longer follow-up period. These patients may have an increased risk of developing ventricular arrhythmias. Therefore, precaution should be taken when using drugs that prolong the QT period, and follow-up with serial electrocardiograms should be planned.

Keywords

Childrendyspepsiaproton pump inhibitorQTcTp-eventricular repolarisation
Type
Original Article
Information
Cardiology in the Young , Volume 33 , Issue 4 , April 2023 , pp. 520 - 524
Check for updates
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gawron, AJ, Feinglass, J, Pandolfino, JE, et al. Brand name and generic proton pump inhibitor prescriptions in the United States: insights from the national ambulatory medical care survey (2006-2010). Gastroent Res Pract 2015; 2015: 689531. DOI 10.1155/2015/689531.CrossRefGoogle ScholarPubMed
Barkun, AN, Bardou, M, Kuipers, EJ, Sung, J. International consensus recommendations on the management of patients with non-variceal upper gastrointestinal bleeding. Ann Intern Med 2010; 152: 101–113.CrossRefGoogle Scholar
Wilhelm, SM, Rjater, RG, Kale-Pradhan, PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol 2013; 6: 443–451. DOI 10.1586/17512433.2013.811206.CrossRefGoogle ScholarPubMed
Cundy, T, Mackay, J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol 2011; 27: 180–185. DOI 10.1097/MOG.0b013e32833ff5d6.CrossRefGoogle ScholarPubMed
William, JH, Nelson, R, Hayman, N, Mukamal, KJ, Danziger, J. Proton-pump inhibitor use is associated with lower urinary magnesium excretion. Nephrology 2014; 19: 798–801. DOI 10.1111/nep.12330.CrossRefGoogle ScholarPubMed
Chrysant, SG. Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias. Expert Rev Cardiovasc Therapy 2019; 17: 345–351. DOI 10.1080/14779072.2019.1615446.CrossRefGoogle ScholarPubMed
Corsonello, A, Lattanzio, F. Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe? Trends Cardiovasc Med 2019; 29: 353–360. DOI 10.1016/j.tcm.2018.10.008.CrossRefGoogle ScholarPubMed
Monitillo, F, Leone, M, Rizzo, C, Passantino, A, Iacoviello, M. Ventricular repolarization measures for arrhythmic risk stratification. World J Cardiol 2016; 8: 57–73. DOI 10.4330/wjc.v8.i1.57.CrossRefGoogle ScholarPubMed
Varró, A, Baczkó, I. Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br J Pharmacol 2011; 164: 14–36. DOI 10.1111/j.1476-5381.2011.01367.x.CrossRefGoogle ScholarPubMed
Neyzi, O, Bundak, R, Gökçay, G, et al. Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 2015; 7: 280–293. DOI 10.4274/jcrpe.2183.CrossRefGoogle ScholarPubMed
Vlachos, K, Georgopoulos, S, Efremidis, M, Sideris, A, Letsas, KP. An update on risk factors for drug-induced arrhythmias. Expert Rev Clin Pharmacol 2016; 9: 117–127. DOI 10.1586/17512433.2016.1100073.CrossRefGoogle ScholarPubMed
Falk, RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989; 111: 107–111.CrossRefGoogle ScholarPubMed
Mitten, MJ, Maron, BJ, Zipes, DP. Task Force 12: legal aspects of the 36th Bethesda conference recommendations. J Am Coll Cardiol 2005; 45: 1373–1375.CrossRefGoogle ScholarPubMed
Park, CH, Kim, EH, Roh, YH, Kim, HY, Lee, SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS ONE 2014; 9: e112558. DOI 10.1371/journal.pone.0112558.CrossRefGoogle ScholarPubMed
Cheungpasitporn, W, Thongprayoon, C, Kittanamongkolchai, W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 2015; 37: 1237–1241. DOI 10.3109/0886022X.2015.1057800.CrossRefGoogle ScholarPubMed
Chowhry, M, Shah, K, Kemper, S, et al. Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use. J Gastroenterol Hepatol 2018; 33: 1717–1721. A paper showing a nonassociation of hypomagnesemia with cardiac arrhythmias.CrossRefGoogle Scholar
Famularo, G, Gasbarrone, L, Minisola, G. Hypomagnesemia and proton-pump inhibitors. Exper Opin Drug Saf 2013; 12: 709–716. DOI 10.1517/14740338.2013.809062.CrossRefGoogle ScholarPubMed
Lazzerini, PE, Bertolozzi, I, Finizola, F, et al. Proton pump inhibitors and serum magnesium levels in patients with Torsades de pointes. Front Pharmacol 2018; 9: 363. DOI 10.3389/fphar.2018.00363.CrossRefGoogle ScholarPubMed
Hess, MW, de Baaij, JH, Broekman, MM, et al. Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitorinduced hypomagnesemia: a case-control study. Pharmacogenet Genomics 2017; 27: 83–88. DOI 10.1097/FPC.0000000000000259.CrossRefGoogle ScholarPubMed
Lorberbaum, T, Sampson, KJ, Chang, JB, et al. Coupling data mining and laboratory experiments to discover drug interactions causing QT prolongation. J Am Coll Cardiol 2016; 68: 1756–1764. DOI 10.1016/j.jacc.2016.07.761.CrossRefGoogle ScholarPubMed
Van Der Bijl, P, Heradien, M, Doubell, A, Brink, P. QTc prolongation prior to angiography predicts poor outcome and associates significantly with lower left ventricular ejection fractions and higher left ventricular end-diastolic pressures. Cardiovasc J Afr 2012; 23: 541–545. DOI 10.5830/CVJA-2012-060.CrossRefGoogle ScholarPubMed
Ramírez, J, van Duijvenboden, S, Young, WJ, et al. Common genetic variants modulate the electrocardiographic Tpeak-to-Tend interval. Am J Hum Genet 2020; 106: 764–778. DOI 10.1016/j.ajhg.2020.04.009.CrossRefGoogle ScholarPubMed
Panikkath, R, Reinier, K, Uy-Evanado, A, et al. Prolonged Tpeak-to-Tend interval on the resting ECG is associated with increased risk of sudden cardiac death. Circ Arrhythm Electrophysiol 2011; 4: 441–447.CrossRefGoogle ScholarPubMed
Bılge, S, Tezel, O, Acar, YA, Cüce, F, Karadaş, Ö., Taşar, M. Investigation of the value of T peak to T end and QTc intervals as electrocardiographic arrhythmia susceptibility markers in acute ischemic stroke. Noro Psikiyatr Ars 2020; 57: 171–176. DOI 10.29399/npa.24996.Google Scholar
Ucar, FM, Ozturk, C, Yılmaztepe, MA. Evaluation of Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio in patients with acute myocarditis. BMC Cardiovasc Disord 2019; 19: 232. DOI 10.1186/s12872-019-1207-z.CrossRefGoogle ScholarPubMed
Küçük, M, Karadeniz, C, Ozdemir, R, Meşe, T. Prolonged T-wave peak-end interval in Down syndrome patients with congenitally normal hearts. Pediatr Int 2018; 60: 513–516.CrossRefGoogle ScholarPubMed
Akın, A, Unal, E, Yıldırım, R, Türe, M, Balık, H, Haspolat, YK. Evaluation of QT dispersion and Tp-e interval in children with subclinical hypothyroidism. Pacing Clin Electrophysiol 2018; 41: 372–375.CrossRefGoogle ScholarPubMed